A Phase I/II Study to Assess the Safety, Tolerability and Efficacy of NouvNeu001 Injection for Mid- to Late-stage Parkinson's Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2024 According to iRegene Therapeutics media release, company announced IND approval of NouvNeu001 by the U.S. FDA for the treatment of mid-to-late stage of Parkinson's disease.
05 Feb 2024 According to iRegene Therapeutics media release, he National Medical Products Administration (NMPA) of China officially approved this trial.
05 Feb 2024 According to iRegene Therapeutics media release, Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com